CASE REPORT: SEQUENTIAL COMBINATION TARGETED THERAPY WITH TYPE I AND II MET INHIBITORS IN A METASTATIC EGFR-MUTATED, MET-AMPLIFIED NSCLC PATIENT WITH ACQUIRED MET Y1230H MUTATION

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for advanced non-small-cell lung cancer (NSCLC) patients.However, most patients will eventually develop resistance.For EGFR-TKI resistance mediated by MET amplification, the combination of EGFR and MET TKIs has shown promising results in early clinica

read more



Problems of taxation of public organizations

The article substantiates recommendations on improving the tax mechanism for regulating the click here activities of public organizations as a special group of tax payers, the problems in the activities of public organizations in the Russian Federation with the use of economic and statistical, etc.are investigated methods of scientific cognition.Th

read more